- Home
- MODD vs ATNM Comparison
MODD vs ATNM Comparison
Compare MODD & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MODD
- ATNM
- Stock Information
- Founded
- MODD 1998
- ATNM 2000
- Country
- MODD United States
- ATNM United States
- Employees
- MODD N/A
- ATNM N/A
- Industry
- MODD Industrial Specialties
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- MODD Health Care
- ATNM Health Care
- Exchange
- MODD Nasdaq
- ATNM Nasdaq
- Market Cap
- MODD 46.3M
- ATNM 49.0M
- IPO Year
- MODD N/A
- ATNM N/A
- Fundamental
- Price
- MODD $0.71
- ATNM $1.79
- Analyst Decision
- MODD
- ATNM Strong Buy
- Analyst Count
- MODD 0
- ATNM 3
- Target Price
- MODD N/A
- ATNM $4.67
- AVG Volume (30 Days)
- MODD 132.7K
- ATNM 458.9K
- Earning Date
- MODD 08-13-2025
- ATNM 08-04-2025
- Dividend Yield
- MODD N/A
- ATNM N/A
- EPS Growth
- MODD N/A
- ATNM N/A
- EPS
- MODD N/A
- ATNM N/A
- Revenue
- MODD N/A
- ATNM N/A
- Revenue This Year
- MODD N/A
- ATNM N/A
- Revenue Next Year
- MODD N/A
- ATNM N/A
- P/E Ratio
- MODD N/A
- ATNM N/A
- Revenue Growth
- MODD N/A
- ATNM N/A
- 52 Week Low
- MODD $0.63
- ATNM $1.03
- 52 Week High
- MODD $2.65
- ATNM $8.09
- Technical
- Relative Strength Index (RSI)
- MODD 45.17
- ATNM 60.07
- Support Level
- MODD $0.68
- ATNM $1.75
- Resistance Level
- MODD $0.78
- ATNM $1.89
- Average True Range (ATR)
- MODD 0.06
- ATNM 0.12
- MACD
- MODD 0.01
- ATNM 0.04
- Stochastic Oscillator
- MODD 37.93
- ATNM 79.59
About MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.